We aimed to answer the question of whether TRAIL is a risk factor or a risk marker in CVDs, particularly taking into consideration major adverse CV events defined as a composite endpoint: nonfatal myocardial infarction, nonfatal stroke and CV death. This evidence concerns the gene TNFSF10 and stroke disorder.